LEN vs PMCB · rev $34.19B vs $8.6M cap
LEN (LEN) versus PharmaCyte Biotech Inc (PMCB) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported PMCB revenue for 2025-04-30 was $0. Net income was $30.7M. PMCB currently screens at market cap $8.6M.
LEN currently screens at market cap $0. PMCB currently screens at market cap $8.6M.
Not investment advice. Open the LEN and PMCB stock pages for the full models.
Not investment advice.